Last reviewed · How we verify
CI-581-a
CI-581-a is a dissociative anesthetic that acts as an NMDA receptor antagonist to produce rapid-onset anesthesia and analgesia.
CI-581-a is a dissociative anesthetic that acts as an NMDA receptor antagonist to produce rapid-onset anesthesia and analgesia. Used for Anesthesia induction and maintenance, Procedural sedation and analgesia.
At a glance
| Generic name | CI-581-a |
|---|---|
| Sponsor | New York State Psychiatric Institute |
| Drug class | NMDA receptor antagonist / Dissociative anesthetic |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Psychiatry |
| Phase | Phase 3 |
Mechanism of action
CI-581-a blocks N-methyl-D-aspartate (NMDA) glutamate receptors, which interrupts pain signal transmission and produces dissociative anesthesia characterized by preserved airway reflexes and analgesia. This mechanism allows for procedural sedation and anesthesia while maintaining spontaneous respiration and protective airway reflexes.
Approved indications
- Anesthesia induction and maintenance
- Procedural sedation and analgesia
Common side effects
- Dissociative effects / emergence reactions
- Increased blood pressure
- Increased heart rate
- Nausea and vomiting
- Dizziness
Key clinical trials
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- Neurobiology of Suicide (PHASE2)
- Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus (PHASE2)
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
- A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression (PHASE2)
- Imaging Depression in Parkinson's Disease (PHASE2)
- Optimal Timing of Ketamine Initiation for SCD Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CI-581-a CI brief — competitive landscape report
- CI-581-a updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI